| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis |
|
Medicine details |
|
| Medicine name | efgartigimod alfa (Vyvgart®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 4542 |
| Indication | As an add‑on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti‑acetylcholine receptor (AChR) antibody positive. |
| Company | argenx |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2022 |
| NICE guidance | TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis |